RE:Investor attitude toward managementThe then what is enormous, new drug application most likely being held up due to the API being in schedule 1, I bet it's approved shortly after official change, furthermore FDA guidelines when released most likely will have strict regulations, that of which MPL is certified for, rescheduling as opposed to full legalization is a gift..massive state level business will remain under state law and cannot participate in the federally regulated realm of medical which likely includes pharmacy's who are federally regulated, insurers, prescriptions much like what we see in Germany, difference with the U.S is no one else took the path MPL is on with FDA audits, CBD drug masterful, D.E.L, DEA import permits, EU GMP/GMP, ANVISA site inspection, once the regs are released in the U.S, MPL can sign deals with national pharmacy chains and begin shipping, ready to rock...and let's be clear...investor deck, recent CC, and MD&A...partner with pending NEW DRUG application...this type of application is submitted once trials are complete/safety:stability/ the entire package, guaranteed back and forth ongoing approval IMO will happen around official reschedule...I would also think some form of NDA exists so MPL doesn't let the cat outta the bag for competitive reasons, after all we do know the API is CBD, don't want to encourage copycat development any sooner than needed through a 505b2 application.